MIM
INZY

MetLife Investment Management’s Inozyme Pharma INZY Stock Holding History

MetLife Investment Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,958
Closed -$66.4K – 2801
2024
Q4 		$66.4K Sell
23,958
-3,991
-14% -$15.2K ﹤0.01% 2713
2024
Q3 		$146K Hold
27,949
– – ﹤0.01% 2451
2024
Q2 		$125K Buy
27,949
+8,743
+46% +$42.4K ﹤0.01% 2489
2024
Q1 		$147K Sell
19,206
-7,301
-28% -$40.1K ﹤0.01% 2354
2023
Q4 		$113K Buy
26,507
+8,472
+47% +$30.1K ﹤0.01% 2546
2023
Q3 		$75.7K Hold
18,035
– – ﹤0.01% 2724
2023
Q2 		$100K Buy
+18,035
New +$107K ﹤0.01% 2679

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's INZY Position: Q1 2025 in Review

MetLife Investment Management sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 23,958 shares — an estimated $66.4K sold.

MetLife Investment Management first reported a position in INZY in Q2 2023 and held it in 7 quarters. The position peaked at $147K in Q1 2024. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • MetLife Investment Management reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • MetLife Investment Management sold 23,958 Inozyme Pharma shares in Q1 2025, an estimated $66.4K.
  • MetLife Investment Management first reported a position in Inozyme Pharma in Q2 2023 and held it in 7 quarters.
  • MetLife Investment Management's Inozyme Pharma position peaked at $147K in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.